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Abstract
Aging at the cellular level is a complex process resulting from accumulation of various damages leading to functional impairment
and a reduced quality of life at the level of the organism. With a rise in the elderly population, the worldwide incidence of
osteoporosis (OP) and osteoarthritis (OA) has increased in the past few decades. A decline in the number and “fitness” of
mesenchymal stromal cells (MSCs) in the bone marrow (BM) niche has been suggested as one of the factors contributing to bone
abnormalities in OP and OA. It is well recognized that MSCs in vitro acquire culture-induced aging features such as gradual
telomere shortening, increased numbers of senescent cells, and reduced resistance to oxidative stress as a result of serial
population doublings. In contrast, there is only limited evidence that human BM-MSCs “age” similarly in vivo. This review
compares the various aspects of in vitro and in vivoMSC aging and suggests how our current knowledge on rejuvenating cultured
MSCs could be applied to develop future strategies to target altered bone formation processes in OP and OA.
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Introduction
Aging is a gradual process marked by the deterioration of
functionality in living organisms with the passage of time. It
is a complex phenomenon known to be affected by a variety of
factors like diet, lifestyle, environment, heredity, and disease. It
slows down the biological mechanisms that aid tissue mainte-
nance, immunity, and health. Disorders like osteoarthritis
(OA), osteoporosis (OP), Alzheimer’s, and Parkinson’s
diseases have been associated with aging, making the life of
patients more challenging as compared to a healthy elderly pop-
ulation. Physically, locomotion and daily activities become dif-
ficult, and vulnerability toward infections increases with aging.
OP is a skeletal disease characterized by a reduction in
bone mineral density, predisposing people to an increased
risk of fracture. The hypothesis that OP is an age-associated
disease and mainly a consequence of estrogen deficiency
was proposed in 1941.1 In 1998, the “unitary model of OP
in postmenopausal women and aging men” was put forward,
this concept combined postmenopausal (involving mainly
trabecular bone) and senile OP affecting both cortical and
trabecular bone.2 The management of OP involves various
pharmacological options that can be divided into antiresorp-
tive and bone stimulatory agents (the former are more
broadly used in clinical practice). On the other hand, OA
is a degenerative joint disease also associated with age that
includes a group of pathologies of joint structures resulting
in pain and disability. There is no disease-modifying treat-
ment for OA, and the management of patients is currently
limited to pain reduction and lifestyle modification. Increase
in age is one of the risk factors for OA.3 However, it is now
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recognized that aging and OA are independent processes, so
that age is one of many contributory factors. Because OA has
been historically described as a disease of the cartilage, most
of the research on aging in OA has been focused on cartilage
tissue.4 More recently, OA has been proposed as a disease of
the whole joint, which is additionally characterized by
severe alterations to subchondral bone as well as by low-
grade systemic and local inflammation.5 Abnormalities in
OA bone include subchondral plate sclerosis, bone marrow
(BM) lesions, and the formation of osteophytes, all are a
result of intermittent abnormal subchondral bone remodel-
ing, which links this aspect of OA to the OP.6
One of the key cellular players in bone physiology is the
osteoblast, a bone-forming cell derived from BM resident
mesenchymal stromal cells (MSCs). BM-MSCs are self-
renewing in vivo, and the shift in their differentiation from
osteogenic to adipogenic lineage with increase in age7–10 can
potentially affect osteoblast formation and bone remodeling, in
general, and thus be a factor in OP and OA development and
pathogenesis. In vitro expanded MSCs have broadly been
defined by their adherence to plastic, ability to give rise to at
least 3 cell lineages (adipogenic, osteogenic, and chondro-
genic); presence of CD73, CD90, and CD105 surface mole-
cules; and absence of CD11b or CD14, CD19 or CD79a, CD34,
CD45, and human leukocyte antigen—antigen D related
(human leukocyte antigen—antigen D related [HLA-DR])—
as defined by the International Society for Cellular Therapy.11
However, the markers used for characterizing in vitro MSCs
are not very useful for the identification of MSCs or their sub-
populations in vivo.12 Most of the experiments for understand-
ing MSC aging have been performed using cultured MSCs, and
attempts have been made to correlate the findings with in vivo
environment. This article addresses the comparison of in vitro
MSC aging with in vivo MSC aging and discusses the concept
of in vivo MSC “rejuvenation” and its future prospects for
novel therapies for OP and OA.
General Theories of Aging
In an attempt to understand MSC aging, it is worth reflecting
on the general theories of cellular and whole body aging.
Among many existing theories, DNA damage, the free rad-
ical (FR), telomere shortening, and stem cell theories have
been discussed in detail recently.13
The DNA damage theory is among the earliest theories
focusing on the mechanism of aging. It refers to the accumula-
tion of DNA damage in every cell with the passage of time.14,15
The sources of DNA damage vary from endogenous toxic
chemicals and reactive oxidative species (ROS) to exogenous
ultraviolet light. This theory has been explored to describe in
vitroMSC aging, particularly in relation to the accumulation of
chromosomal instability following prolonged culture.16
The FR theory or the theory of ROS proposes that the
continuous process of FR generation in metabolism causes
damages to tissues owing to the presence of free and
unpaired electron on the oxygen atomic outer shell.17
Antioxidants in the body combat the negative effects of
ROS. However, when the balance between production of
antioxidants and FR is lost, oxidative stress (OS) develops.18
This can then lead to oxidation of nucleic acids, severely
damaging the DNA and resulting in mutagenesis and mod-
ification of the transcription of specific genes. In terms of
MSC aging, this theory has primarily been applied to
describe the decrease in adhesion of MSCs19 and the
increased bias toward adipogenic differentiation.20
The telomere shortening theory postulates that with each
cell division, the length of telomeres in mature cells keeps
reducing due to the attrition and the lack of telomerase activ-
ity, an enzyme responsible for telomere elongation. In BM-
MSCs, telomere attrition can also occur leading to cellular
senescence,21 although its exact mechanism remains
unclear, as in MSCs, telomerase activity is present but low.
While telomere length decreases with an individual’s age,
recent data suggest that after the age of 75, it becomes posi-
tively correlated with age implying its significance for sur-
vival in the very old age.15,22 In terms of MSC aging, this
theory has been extensively tested using serially passaged
MSCs, where an average 17 base pair telomere loss with
each population doubling was confirmed.21,23
The stem cell theory of aging postulates a decline in stem cell
number and functionalities as a potential effect of aging.24–26
Schultz and Sinclair have discussed that the probable causes of
cellular aging (i.e., the abovementioned telomere attrition, DNA
damage, and cellular senescence) can also be applied to stem
cells.15 Fukada et al. have not only described the aging of stem
cells but have also connected the other theories with the stem cell
theory to explain the complex progression of aging.18 As BM-
MSCs can be viewed as true stem cells,27 the stem cell theory is
linked to each of the theories mentioned above.
Finally, the theories of epigenetic alterations24 and decline
in protein homeostasis25 have also gained importance in the
recent past. While all these theories have been mentioned
separately, they are interlinked and lead to one another. Mito-
chondrial damage often leads to the production of ROS that
interact with molecules in the body affecting them nega-
tively.24 The accumulation of the oxidative by-products of
ROS interactions, with time, causes DNA damage and geno-
mic instability resulting in cellular senescence. This disturbs
the self-renewal capacity of stem cells in their microenviron-
ment which is known to interrupt the normal functioning of
different types of stem and other cells in the BM.18,28
In Vitro MSC Aging
This section outlines the recent findings of in vitro MSC
aging as well as the current methods used to track MSC
aging in culture.
Passage Dependent
It is well accepted that MSC expansion in culture results in
their accelerated aging.23,29 Colony-forming unit fibroblast
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assay has been one of the oldest methods to document the
loss of proliferation in cultured MSCs during their extended
passaging.30 Many independent studies have later documen-
ted that this loss of proliferation is correlated with a decline
in the telomere length with increasing population doublings
(PD).23,29 The senescence-associated b-galactosidase (SA-b-
gal) enzyme activity is increased in senescent cells and simi-
larly, the number of SA-b-gal positive cells have been
reported to escalate with increase in PDs.29,31 Regarding the
potentials of MSC for differentiation, a study by Vacanti
et al. was among the first to show a significant decrease in
the differentiation potential of cultured BM-MSCs (porcine)
into osteogenic lineage in the late passages as compared to
early passages. The late passages also exhibited actin accu-
mulation, reduced adherence to substrates, and increased
activity of b-galactosidase all of which are indicative of
cellular aging.32 More recently, Yao et al. have highlighted
the effects of in vitro aging on wound healing ability of
MSCs derived from mouse fat pads.33
In addition to the abovementioned changes, Bonab et al.
observed anomalies in the morphology of human BM-MSCs
with increasing passage number and suggested that in vitro
aging of MSCs begins from the minute they are plated on
plastic.23 One of the potential reasons for such accelerated
aging could be the fact that MSCs placed in culture receive
conditions supportive of their enhanced proliferation that
goes far beyond its physiological demands (Fig. 1). Impor-
tantly, MSCs are cultured under hyperoxia, where they con-
sume oxygen at a high rate,34 leading to high levels of ROS
that accumulate with prolonged culture of MSCs.35
One of the suggested solutions to such accelerated aging
could involve growing MSCs under hypoxic conditions.
Under long-term exposure to hypoxia, MSCs may adapt
themselves to low oxygen levels, decreasing their oxygen
consumption and reducing their ROS production.23 This
would lead to improved MSC survival and reduced apopto-
sis. Interestingly, the migration of adipose tissue MSCs may
also be induced by hypoxia as shown in animals.36
Donor Age Dependent
The closest to understanding in vivo aging of BM-MSCs in
humans has so far been obtained from the studies where the
growth and differentiation of MSCs from young and old
donors have been compared using the same growth condi-
tions in vitro. For example, Mueller and Glowacki observed
a decline in the osteogenic differentiation potential of
MSCs from human femoral BM collected from subjects
above the age of 60 (old) compared to subjects below the
age of 50.8 Stenderup et al. studied the maximal in vitro life
span and in vivo bone formation in mice of human BM-
MSCs from young (18–29 years old) and old (68–81 years
old) individuals. Their results suggested that the life span in
cumulative PDs from the older donors was significantly
lower than that of the younger donors and that the MSCs
from the older donors exhibited accelerated senescence
with each PD. However, they did not find any change in
the total number of senescent cells (using SA-b-gal assay)
or in the telomere lengths in the early passage cells of both
groups of donors. Interestingly, MSCs from both the donor
groups were able to form similar amounts of mineralized
matrix and in vivo bone formation in mice. This provided
the first indication that MSC aging in vitro possibly occurs
faster than in vivo MSC aging.29
Baxter et al. measured the mean telomere restriction frag-
ment at exactly the same “culture age” (16 PDs) of human
BM-MSCs and found a significant decrease in the length of
telomeres in the MSCs of older donors (59–75 years old)
compared to the younger ones (0–18 years old).21 Stolzing
et al. measured ROS and superoxide dismutase levels to
compare these and other indices of in vitro aging in BM-
MSC cultures from younger and older donors. They
observed an increase in all tested indices of aging in cultured
MSCs from older donors, indicating a reduction in their
“fitness.”31 Peffers et al. have used protein analysis of
human MSCs from young and old donors and have discov-
ered alterations in energy metabolism in older donors.37
These studies suggested that BM-MSCs most probably
“age” in vivo, but the use of cultured MSCs, which them-
selves undergo rapid “aging” in vitro, is not an optimal
material to understand in vivo BM-MSC aging and other
approaches need to be developed.
Methods to Track MSC Aging in Culture
Tracking in vitro aging of MSCs has been performed using a
variety of methods, some of which have been mentioned
already. One of the most intriguing observations noted in
many studies pertains to considerable changes in MSC size
and morphology. Initial passages of cultured MSCs retain
their characteristic spindle-like morphology, but the cells
after a few PDs appear enlarged and more granular.23,38,39
The relative area of BM-MSCs in the late passages increases
over 10-fold compared to early passages (from 5 mm2 up to
50 mm2, respectively).40 This increase in size appears to
Figure 1. A proposed model highlighting the different mechanisms
of bone marrow–mesenchymal stromal cells (MSCs) aging in vitro
and in vivo. 2-D ¼ 2-dimensional; 3-D ¼ 3-dimensional; ECM ¼
extracellular matrix; HSC ¼ hematopoietic stem cells.
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parallel with the increase in actin stress filaments.29 A sim-
ilar increase in size and actin filaments in late passage cells
has also been observed in late passage of cultured osteo-
blasts.41 While the reasons for these morphological changes
in MSCs remain unknown, precise measurements of MSC
size could provide a rapid estimate of an MSC aging “status”
during their culture in vitro.
Immunophenotyping using several antibodies have been
performed to identify surface markers specific for aged
MSCs. An increase in the expression of CD44 and a decrease
of Stro-1 molecule, CD71, CD90, CD105, CD146, and
CD274 were detected in human BM-MSCs with increasing
PDs as well as in old donors.31,42,43 However, measuring
surface markers as indicators of MSC aging remains contro-
versial; for example, while some studies have observed a
decrease in CD106 expression during MSC passaging,44 oth-
ers documented its gradual increase,45 which is most likely
due to the different culture conditions used. Gene expression
and DNA methylation marks may, in this respect, be more
useful.39,46 For example, the analysis by Wagner et al.
revealed over 1,000 transcripts upregulated at least 2-fold
in senescent MSCs and over 500 transcripts downregu-
lated.39 More recently, Peffers et al. have shown that the
expression of miR-199b-5p was reduced in MSCs from old
donors and correlated with a decline in energy metabolism
and cell survival.37 Duscher et al. worked on murine adi-
pose–derived MSCs and observed a decline with age in
hypoxic transcription factor (Hif1a) and C-X-C motif che-
mokine ligand 12 (CXCL12) highlighting their impaired
therapeutic potential.36
In Vivo MSC Aging
In vivo tracking of MSC aging has so far been performed
only in animal models. While the available literature broadly
suggests a decline in MSC frequency with aging,47,48 the
issue remains controversial. For example, some studies have
indicated a decline in MSC number in older individuals,31,49
whereas other scientists did not find any significant
changes.43,50 This could be due to different volumes of
BM aspirate used as well as different processing methodol-
ogies (e.g., direct plating vs. density centrifugation).51,52
One of the most interesting features of MSCs from older
individuals appears to be their reduced propensity for osteo-
genic differentiation with increased bias toward adipogenic
differentiation. The loss of balance between osteogenic–adi-
pogenic differentiation leads to increased BM adiposity and
is seen in OP.7,10,28,53 The exact mechanism underlying the
adipogenic bias is yet to be clearly understood. Recent stud-
ies have identified microRNAs miR-27a,54 miR-27b, Let-
7G, and miR-106a55 that are necessary for maintaining the
osteogenic differentiation potential of MSCs and have dis-
played a significant decline with aging.
As mentioned in the above sections, the great majority of
studies investigating the aging of human BM-MSCs have
been performed on MSCs expanded in culture. As these
cultured MSCs undergo an aging process as a result of exten-
sive proliferation during consecutive PDs, these studies pro-
vide only indirect evidence of how MSCs may age in vivo.
Furthermore, in vivo BM-MSC niche is not mirrored when
these cells are cultured and expanded on the plastic surfaces.
Thus, it can be proposed that in vivo and in vitro aging of
MSCs may have both common (overlapping) and nonover-
lapping features (Fig. 1).
Intrinsic Factors: Proliferation Burden
In vitro MSC aging could, to a large extent, be due to telo-
mere erosion occurring as a result of their rapid proliferation
in response to growth factors (GFs) present in fetal calf
serum. MSCs grown in medium supplemented with human
platelet lysates grow even faster.56 As shown for fibro-
blasts,57 the chronic exposure of MSCs to high doses of
growth promoting factors could lead to the downregulation
of GF receptors and resistance to these factors and eventu-
ally resulting in cellular senescence.
In contrast, there is no compelling evidence that MSCs in
vivo are rapidly cycling cells; in the opposite, earlier studies
have documented that the in vivo MSCs identified based on
Stro-1 expression are slow cycling.58 In vivo MSC prolifera-
tion, and factors that influenced it, is not fully understood,
but the fact that human bone constantly undergoes a process
of remodeling so that every 10 years mature bone cells are
renewed59 suggests that in vivo MSCs should undergo rare
asymmetrical divisions in order to both maintain their own
pool and also to provide enough osteoblast progenitors to
facilitate bone remodeling. Because of this slow-cycling
nature of in vivo MSCs, their aging due to telomere erosion
is unlikely to be the primary factor in their in vivo aging
process. It is noteworthy that following bone fracture, the
local MSC proliferation response is activated60; furthermore,
local injections of platelet-derived factors can temporarily
increase their local pool.61 There is some evidence that blood
platelet responses following fracture may also exert a sys-
temic effect and “activate” these slow-cycling MSCs.62
Environmental Factors: Stem Cell Niche
The stem cell niche is commonly defined as an in vivo reg-
ulatory microenvironment where stem cells reside.63 MSC
niches in human BM are poorly understood but are believed
to be primarily in the perivascular and bone-lining loca-
tions.64 Notably, cells expressing a common BM-MSC mar-
ker LNGFR/CD271 may be more broadly distributed as
adventitial reticular cells, which are connected to each other
via long projections, forming the “backbone” of the BM
stroma.65 These topographical differences should be taken
into account when considering how BM-MSCs may age in
vivo. For example, perivascular BM regions are believed to
be more oxygenated compared to endosteal regions66 and so
perivascular MSCs could theoretically be more exposed to
OS compared to bone-lining MSCs. However, recent direct
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in vivo measurements of local oxygen tension in the BM of
live mice showed perisinusoidal rather than endosteal
regions to be more hypoxic suggesting that the BM hypoxic
landscape is determined not only by vascularity (oxygen
supply) but also by the area’s cellularity (consumption).67
As the MSC niche in BM generally has low oxygen level,
they must be adapted to use mainly an anaerobic metabolism
(glycolysis) for their energy supply, which appears to limit
the MSC proliferation to avoid OS.35 A phenomenon called
extra physiological oxygen shock/stress (EPHOSS) was first
noted for hematopoietic stem cells (HSCs) when BM was
collected and processed in ambient air (21% oxygen).34 The
EPHOSS is associated with loss of stemness and is related to
increased level of mitochondrial ROS.34 Although the level
of ROS is induced during in vitro MSC aging, this event has
been reported at similar levels between young and old ani-
mals (rats).68 It was proposed that the increase of ROS was
more related to microenvironment of culture than chronolo-
gical age.
Environmental Factors: Effect of Hormones and GFs
The significant drop of sex hormone levels and the increase
of the glucocorticoids production and activity are hormonal
hallmarks of human aging that are associated with reduced
bone mass.69,70 The functional capacities of MSCs have
been linked to these age-related hormones. Estrogen can
induce osteogenic rather than adipogenic differentiation of
MSCs.71 Conversely, testosterone promotes the proliferation
of MSCs and preserves their stemness.72 This may explain a
more prominent decline in in vivo MSC numbers in females
compared to males.43,73 The in vivo effect of glucocorticoids
on MSCs is not clear, but these hormones have a negative
effect on osteogenesis as inducer of the apoptosis in osteo-
blasts and suppressor of their differentiation and prolifera-
tion.74 In contrast to the in vivo hormones, the hormones
incorporated into the MSC expansion or differentiation
medium could have different effects. For example, very high
doses of glucocorticoids added to MSC differentiation media
stimulate their differentiation into fat, cartilage, bone, and
muscle cells.75
An interesting GF that can be implicated in in vivo MSC
aging is insulin-like growth factor 1 (IGF-1). The blood and
bone matrix levels of IGF-1 are decreased significantly with
aging and correlated with reduced bone mineral density.76
The osteogenic differentiation potential of MSCs is
enhanced by the effect of IGF-1 as shown in mouse IGF-1
model of receptor knockout.77 Thus, it could be assumed that
the reduction in IGF-1 effect on MSCs is another character-
istic of their in vivo aging.
Environmental Factors: The Cross Talk with
Other BM Cells
The cross talk between HSCs and MSCs within BM is a
dynamic process that affects the functions of both cells and
probably their aging as well. Within their common niche,67
HSCs also undergo alterations with aging. Studies in animals
have confirmed the process called “myeloid skewing,”
which includes a decline in the number of lymphoid progeni-
tors and a bias toward the formation of myeloid progenitors
with increasing age.78
It is quite likely that both types of stem cells are influ-
enced by similar “aging forces.” In fact, some studies have
indeed shown that BM-HSC and MSC aging occur in par-
allel.50 Interestingly, MSCs can help HSCs to reduce their
intracellular ROS levels via several mechanisms including
C-X-C chemokine receptor type 4 (CXCR4)/CXCL12
(stromal cell-derived factor 1 [SDF-1]) interactions and
an uptake of ROS via connexin gap junction.57 While there
has been more focus on the niche-related mechanisms that
might induce aging of HSCs (changes in connexin gap
junction and role of SDF-1), it is still unclear whether these
changes in the in vivo niche/milieu could also affect the
aging of MSCs. It will be valuable to determine to what
extent the surrounding cells (e.g., HSCs) would affect the in
vivo MSC aging.
Mature MSC and HSC descendants and the molecules
they release may also play a significant role in MSC aging.
For example, it is well known that marrow adiposity (i.e., the
numbers of fat cells, which are mature MSC descendants)
increase with age.79 The factors that mature adipocytes
release into their environment (adipokines and other adipose
tissue hormones) are likely to influence the neighboring
MSCs, potentially creating a “vicious loop” that drives pre-
ferential MSC differentiation toward fat rather than bone,
which likely impacts also on the decline in hematopoiesis
in this area and the propensity to OP.
Rejuvenation of OP and OA MSCs
Early studies have shown a decline in the number of osteo-
blast progenitors in the BM of OP patients compared with
age-matched controls.80 At least in females, this could be
explained by an altered balance in the systemic levels of
hormones such as estrogen and testosterone. Culture-
expanded MSCs from OP patients have been shown to pos-
sess lower proliferative and osteogenic capacities81 (i.e., to
exhibit distinctive marks of premature in vitro aging) com-
pared to healthy individuals. Recent evidence suggests that
this could be due to the overexpression of osteogenic inhi-
bitors in OP MSCs.82 A recent study by Zhou et al. has
identified a number of differentially expressed genes that are
up- or downregulated in OP MSCs, which could not only be
used as a biomarker for OP,83 but also serve as potential
targets for therapeutic modulation to rejuvenate OP MSCs.
MSCs extracted from the areas of subchondral bone damage
in hip OA patients also appear to acquire several abnormal-
ities indicative of premature aging (e.g., reduced in vitro
proliferative and mineralization capacities).84 It remains to
be investigated whether putative accelerated aging of OP and
OA MSCs in vitro is reflective of their accelerated aging in
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vivo. However, as mentioned in the above sections, OP
MSCs may indeed reside in a considerably modified in vivo
niche that is markedly enriched in marrow fat.53 Changes in
marrow adiposity and an increased cellular necrosis have
also been detected in the affected areas of OA subchondral
bone.85 This suggests that targeting putative in vivo aging in
OP and OA MSCs may be performed indirectly, by targeting
their in vivo niches (Table 1).
Abdallah et al. tested the impact of serum from young
(20–30 years old) and old (70–84 years old) donors on MSC
differentiation and proliferation and found a significant
decline in osteogenic differentiation potential of MSCs
grown in serum from old donors.87 This suggests the exis-
tence of, yet unknown, factors in the serum or plasma from
“younger” donors that could potentially be used systemi-
cally to reduce the rate of in vivo aging of MSCs, including
OP MSCs. Similarly, Sun et al. cultured MSCs from young
and old mice on plastic, young extracellular matrix (ECM)
and old ECM and have shown that the number and quality
of MSCs from old mice could be improved when cultured
on young ECM.88 In vivo ECM modulation could thus be
another strategy to rescue or rejuvenate MSCs in OP and
possibly, OA.
The “mechanistic target of rapamycin” (mTOR) is a ser-
ine/threonine protein kinase of the phosphatidylinositol-
3-OH kinase (PI3K) family, which regulates cell growth,
metabolism, and functions in two complexes—mTOR com-
plex 1 and mTOR complex 2. This pathway has been the
target of wide interest ever since it was discovered, and it has
been suggested that inhibition of this pathway could extend
the life span of rodents.89 The role of rapamycin in the dif-
ferentiation of MSCs or their progenitors has also been stud-
ied, but to date, the results are controversial,90 suggesting
that the drug can either encourage91 or discourage92 osteo-
genic differentiation of MSCs. This implies the need for
further exploring this pathway and related molecules to
understand their function in MSC aging and their possibility
to rejuvenate aged MSCs.
Sirtuins (SIRT) genes have similarly proved to be of
significant importance in regulating aging.93 Simic et al.
performed experiments on mice with MSC specific sirtuin
1 (Sirt-1) knock out gene and found that Sirt-1 regulates the
MSC differentiation by the deacetylation of b-catenin.94
This suggests that targeting this gene using gene therapy can
be used for halting or reversing aging of MSCs. However,
further studies are required to understand the connecting
links between the SIRT genes and this signaling cascade to
ultimately apply this approach for preventing aging of MSCs
in vivo and in diseases such as OP and OA.
Conclusions and Future Directions
Currently, our understanding of MSC aging in vitro consid-
erably surpasses our understanding of MSC aging in vivo. In
order to move forward in the study of human MSC aging in
vivo, an ability to isolate a pure population of uncultured
MSCs represents an initial and critical step. Up to now, a
broad consensus on the combination of markers to purify
human BM-MSCs does not exist, although markers such as
CD271 and MSCA-1,12 possibly in combination with
CD140a,27 appear to be the most promising.
Methods currently used for the detection of aging in cul-
tured MSCs could, in principle, be used for the study of
aging of uncultured MSCs, although these need to be
adapted to be used with very low numbers of cells as BM-
MSCs are very rare in vivo. Research based on molecules
like prelamin and lipofuscin, which can be65 detected at the
later stages of MSC culture in vitro, is a promising approach
for identifying “aged” and senescent MSCs in vivo.39,95 It
will be interesting to investigate the change of size of BM-
MSCs with aging in vivo and compare it to the acknowl-
edged change of size in vitro40 to possibly use cell size as
an indicator of MSC aging in vivo. Churchman et al. have
demonstrated a decline in the expression of molecules like
connexin 43 in uncultured human BM-MSCs in older donors
using quantitative polymerase chain reaction,96 suggesting
that it, and similar surface molecules, could be considered
further as potential indicators of aged MSCs in vivo.
The ability to identify MSCs in situ and extract them less
invasively from their native niches would then lead to a
better understanding of their local environments, which
could then be reconstructed and modeled using
3-dimensional (3-D) “organ” cultures. These organoids
could then be used for developing and screening new
Table 1. Abnormalities in MSCs or Their In Vivo Niches as Potential Targets for OP and OA MSC Rejuvenation.
Abnormality Intrinsic/Environmental OP OA
MSC number Intrinsic Reduced80 Unbalanced in damaged areas84,86
Signaling pathways in
MSC
Intrinsic Reduced osteogenesis due to
overexpression of osteogenic
inhibitors82
Abnormal homing due to altered TGFb
signaling86 and chemokine receptor
expression84
MSC niche: ECM Environmental Increased BM adiposity53 Increased BM adiposity85
Increased levels of free TGFb86
MSC niche: Neighboring
cells
Environmental Accelerated osteoclast activation53 Increased numbers of osteoclasts in damaged
areas86
Note. BM ¼ bone marrow; ECM ¼ extracellular matrix; MSC ¼ mesenchymal stromal cells; OA ¼ osteoarthritis; OP ¼ osteoporosis; TGFb ¼ transforming
growth factor b.
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rejuvenation compounds to target OP and OA MSCs in 3-D
environments most closely resembling their native niches.
These approaches should lead to a better understanding of
MSC aging in vivo. Considering that MSCs form an integral
part of the musculoskeletal system and that OP and OA have
been associated with aging,1,3 prevention of MSC aging in
vivo could lead to novel therapies to target altered bone
formation in OP and OA.
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